These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23883923)

  • 1. EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
    Jassem J; Dziadziuszko R
    Lancet Oncol; 2013 Sep; 14(10):916-7. PubMed ID: 23883923
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
    Mitsuoka S; Kawaguchi T; Kubo A; Isa S; Asai K; Uji M; Watanabe T; Sawa K; Yoshimoto N; Oka T; Nakai T; Suzumura T; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Kudoh S; Hirata K
    Expert Opin Pharmacother; 2016; 17(2):193-203. PubMed ID: 26781399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising therapy for EGFR-addicted NSCLC: just the start.
    Govindan R; Subramanian J
    Lancet Oncol; 2012 Mar; 13(3):216-7. PubMed ID: 22285167
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EGFR in non-small-cell lung cancer.
    Doroshow JH
    N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
    [No Abstract]   [Full Text] [Related]  

  • 8. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 10. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Zalcman G; Bergot E
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
    [No Abstract]   [Full Text] [Related]  

  • 12. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
    Dafni U; Karlis D; Smit E; Peters S
    Lung Cancer; 2014 Jun; 84(3):314-5. PubMed ID: 24685307
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Curr Med Res Opin; 2015 Jan; 31(1):25-33. PubMed ID: 25329826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
    Cappuzzo F
    J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643
    [No Abstract]   [Full Text] [Related]  

  • 19. Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
    Liu D; Yang Y; Zhao S
    J Formos Med Assoc; 2014 Mar; 113(3):141-2. PubMed ID: 24630031
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.